These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 24798623)

  • 41. von Willebrand Factor Antigen Predicts Outcomes in Patients after Liver Resection of Hepatocellular Carcinoma.
    Schwarz C; Fitschek F; Mittlböck M; Saukel V; Bota S; Ferlitsch M; Ferlitsch A; Bodingbauer M; Kaczirek K
    Gut Liver; 2020 Mar; 14(2):218-224. PubMed ID: 30428508
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Potential Clinical Targets in Hepatopulmonary Syndrome: Lessons From Experimental Models.
    Raevens S; Fallon MB
    Hepatology; 2018 Nov; 68(5):2016-2028. PubMed ID: 29729196
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential diagnosis of hepatopulmonary syndrome (HPS): Portopulmonary hypertension (PPH) and hereditary hemorrhagic telangiectasia (HHT).
    Krynytska I; Marushchak M; Mikolenko A; Bob A; Smachylo I; Radetska L; Sopel O
    Bosn J Basic Med Sci; 2017 Nov; 17(4):276-285. PubMed ID: 28759737
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hepatopulmonary syndrome is associated with the presence of hepatocellular carcinoma in patients with decompensated cirrhosis.
    Soulaidopoulos S; Goulis I; Giannakoulas G; Panagiotidis T; Doumtsis P; Karasmani A; Oikonomou T; Tzoumari T; Karvounis H; Cholongitas Ε
    Ann Gastroenterol; 2017; 30(2):225-231. PubMed ID: 28243044
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of autophagy ameliorates pulmonary microvascular dilation and PMVECs excessive proliferation in rat experimental hepatopulmonary syndrome.
    Xu D; Chen B; Gu J; Chen L; Belguise K; Wang X; Yi B; Lu K
    Sci Rep; 2016 Aug; 6():30833. PubMed ID: 27480323
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hepatopulmonary syndrome: What we know and what we would like to know.
    Grilo-Bensusan I; Pascasio-Acevedo JM
    World J Gastroenterol; 2016 Jul; 22(25):5728-41. PubMed ID: 27433086
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hepatopulmonary Syndrome and Liver Transplantation: A Recent Review of the Literature.
    Cosarderelioglu C; Cosar AM; Gurakar M; Dagher NN; Gurakar A
    J Clin Transl Hepatol; 2016 Mar; 4(1):47-53. PubMed ID: 27047772
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hepatopulmonary Syndrome.
    Lv Y; Fan D
    Dig Dis Sci; 2015 Jul; 60(7):1914-23. PubMed ID: 25732713
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of increased von Willebrand factor levels on primary hemostasis in thrombocytopenic patients with liver cirrhosis.
    Wannhoff A; Müller OJ; Friedrich K; Rupp C; Klöters-Plachky P; Leopold Y; Brune M; Senner M; Weiss KH; Stremmel W; Schemmer P; Katus HA; Gotthardt DN
    PLoS One; 2014; 9(11):e112583. PubMed ID: 25397410
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pulmonary vascular abnormalities in cirrhosis.
    Herve P; Le Pavec J; Sztrymf B; Decante B; Savale L; Sitbon O
    Best Pract Res Clin Gastroenterol; 2007; 21(1):141-59. PubMed ID: 17223502
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hepatopulmonary syndrome.
    Koch DG; Fallon MB
    Clin Liver Dis; 2014 May; 18(2):407-20. PubMed ID: 24679503
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Von Willebrand factor antigen for detection of hepatopulmonary syndrome in patients with cirrhosis.
    Horvatits T; Drolz A; Roedl K; Herkner H; Ferlitsch A; Perkmann T; Müller C; Trauner M; Schenk P; Fuhrmann V
    J Hepatol; 2014 Sep; 61(3):544-9. PubMed ID: 24798623
    [TBL] [Abstract][Full Text] [Related]  

  • 53. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis.
    Ferlitsch M; Reiberger T; Hoke M; Salzl P; Schwengerer B; Ulbrich G; Payer BA; Trauner M; Peck-Radosavljevic M; Ferlitsch A
    Hepatology; 2012 Oct; 56(4):1439-47. PubMed ID: 22532296
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension.
    La Mura V; Reverter JC; Flores-Arroyo A; Raffa S; Reverter E; Seijo S; Abraldes JG; Bosch J; García-Pagán JC
    Gut; 2011 Aug; 60(8):1133-8. PubMed ID: 21427197
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hepatopulmonary syndrome: prevalence and predictors in Egyptian cirrhotic patients.
    El Makarem MA; Elakad A; Ali A; Abd-Elkader M; Sayed AF; Taha A; Abd-Elrhman T
    Trop Gastroenterol; 2011; 32(1):25-30. PubMed ID: 21922852
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Von-Willebrand factor as a predictor of three-month mortality in patients with liver cirrhosis compared to MELD score.
    Curakova Ristovska E; Genadieva-Dimitrova M; Caloska-Ivanova V; Misevski J
    Acta Gastroenterol Belg; 2019; 82(4):487-493. PubMed ID: 31950803
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.